Lifting the Fog of Chemobrain

 Sometimes it’s incredibly frustrating to get the word out about BrainHQ and how it can help people. Let’s take people experiencing “chemobrain” (cognitive losses resulting from chemotherapy) as an example. Clinical scientists have shown that using BrainHQ exercises virtually re-normalizes the brain of an individual suffering from chemobrain. Benefits clearly extend beyond those skills and abilities that […]The post Lifting the Fog of Chemobrain appeared first on "On the Brain" with Dr. Michael Merzenich.
Source: On the Brain by Dr. Michael Merzenich, Ph.D. - Category: Neurologists Authors: Tags: Brain Fitness Brain Plasticity Brain Science BrainHQ Chemobrain Cognitive impairments Neuroscience Posit Science brain training cancer chemofog chemotherapy drugs Source Type: blogs

Related Links:

;a ML Abstract In 2016, there were 17.2 million of cancer cases which caused 8.9 million of deaths worldwide. Of all cancers, ranked by absolute years of life lost, brain and central nervous system cancer were classified in the nine position between 2006 and 2016. Glioblastoma is the most common malignant primary brain tumour and comprises 80% of malignant tumours. Therapeutic approach usually involves the combination of surgery and radiotherapy, which present a high risk for the patient and are not always effective in the most aggressive cases. Chemotherapy commonly includes a specific number of cycles given over...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
ConclusionsThis study demonstrates the feasibility of using a single-mouse design for assessing the antitumor activity of an agent, while encompassing greater genetic diversity representative of childhood cancers. PLX038A was highly active in most xenograft models, and tumor sensitivity to PLX038A was correlated with sensitivity to irinotecan, validating the single-mouse design in identifying agents with the same mechanism of action. Biomarkers that correlated with model sensitivity included wild-typeTP53, or mutantTP53 but with a mutation in53BP1, thus a defect in DNA damage response. These results support the value of th...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ville Malignant gliomas are one of the deadliest forms of brain cancer and despite advancements in treatment, patient prognosis remains poor, with an average survival of 15 months. Treatment using conventional chemotherapy does not deliver the required drug dose to the tumour site, owing to insufficient blood brain barrier (BBB) penetration, especially by hydrophilic drugs. Additionally, low molecular weight drugs cannot achieve specific accumulation in cancerous tissues and are characterized by a short circulation half-life. Nanoparticles can be designed to cross the BBB and deliver their drugs within the brain, thus ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 8 January 2020Source: Pharmacological ResearchAuthor(s): Kishore Banik, Abhishek Manoj Ranaware, Harsha Choudhary, Nitesh Thakur, Sosmitha Girisa, Vishwas Deshpande, Lu Fan, Savita Pravin Nalawade, Gautam Sethi, Ajaikumar B. KunnumakkaraAbstractThe World Health Organization (WHO) has documented that cancer is the second foremost reason for death worldwide. Various factors are responsible for cancer, for instance, exposure to different physical, chemical and biological carcinogens, infections, hereditary, poor dietary habits and lifestyle etc. Cancer is a preventable disease if detected at...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
AbstractIn the pediatric population, brain tumors represent the most commonly diagnosed solid neoplasms and the leading cause of cancer-related deaths globally. They include low-grade gliomas (LGGs), medulloblastomas (MBs), and other embryonal, ependymal, and neuroectodermal tumors. The mainstay of treatment for most brain tumors includes surgical intervention, radiation therapy, and chemotherapy. However, resistance to conventional therapy is widespread, which contributes to the high mortality rates reported and lack of improvement in patient survival despite advancement in therapeutic research. This has been attributed t...
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research
(Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)) Brazilian study uncovered an anticancer chemotherapy resistance mechanism related to amyloid aggregation of mutant p53. The research was conducted in cells derived from glioblastoma, a super aggressive brain tumor, and in living cells. The results open up new opportunities for the development of more effective therapies against cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In the original publication of the article, the authors wish to note an error in the section “Funding”.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Abstract Glioblastoma multiforme (GBM), a greatly aggressive malignancy of the brain, is correlated with a poor prognosis and low rate of survival. Up to now, chemotherapy and radiation therapy after surgical approaches have been the treatments increasing the survival rates. The low efficacy of mentioned therapies as well as their side-effects has forced researchers to explore an appropriate alternative or complementary treatment for glioblastoma. In experimental models, it has been shown that curcumin has therapeutic potentials to fight against GBM. Given that curcumin has pharmacological effects against cancer s...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
AbstractBackgroundWe investigated the risk factors for leptomeningeal carcinomatosis (LMC) and compared clinical efficacies of various treatment modalities including intrathecal (IT) chemotherapy in patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations.MethodsUsing clinical research data from the Asan Medical Center, we retrospectively analyzed data of patients diagnosed with LMC, confirmed via cerebrospinal fluid (CSF) analysis from January 2008 to December 2017.ResultsWe identified 1189 patients with lung adenocarcinoma harboring EGFR mutations. Among these, 9.8% had a median durat...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conclusion A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Neurologists | Neurology | Neuroscience | Science | Training | Universities & Medical Training